Medivir Articles

Medivir/J&J, Merck & Co and Bristol-Myers to present at Int Liver Congress

9 April 2013

Janssen gains FDA approval of Invokana for type 2 diabetes; files simeprevir NDA

2 April 2013

Clinical updates at ROI meeting on GSK's dolutegravir and Medivir's simeprevir

7 March 2013

Bristol-Myers expands hepatitis C accord with Medivir and Janssen

18 April 2012

Bristol-Myers links with Tibotec for Ph II combination study in hepatitis C patients

5 December 2011

Medivir’s new subsid BioPhausia AB sells generics business to Bluefish

30 August 2011

Medivir renegotiates deal with Meda, receiving $45 million for US rights for Xerese; Meda passes this and Elidel to Valeant

30 June 2011

Medivir to buy BioPhausia for around $90 million

12 April 2011

Medivir enters dengue virus R&D collaboration with Johnson & Johnson unit

15 February 2011

GlaxoSmithKline bags rights to Futura’s pain drug TPR100; Biospherics gets patent to develop Dtagatose from Kentucky University

1 July 2010

Showing 1-10 of 10 articles

Go to beginningPrevious
  • 1
NextGo to end